Article

AstraZeneca C.E.O. to Step Down

David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.

Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.

Read the full story: http://hcp.lv/IhDj2O

Source: The New York Times

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Kimberly Westrich, MA, chief strategy officer, NPC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo